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Abstract: Traumatic brain injury (TBI) is widespread and leads to death and disability in 
millions of individuals around the world each year. Overall incidence and prevalence of TBI 
are likely to increase in absolute terms in the future. Tackling the problem of treating TBI 
successfully will require improvements in the understanding of normal cerebral anatomy, 
physiology, and function throughout the lifespan, as well as the pathological and recupera-
tive responses that result from trauma. New treatment approaches and combinations will 
need to be targeted to the heterogeneous needs of TBI populations. This article explores and 
evaluates the research evidence in areas that will likely lead to a reduction in TBI-related 
morbidity and improved outcomes. These include emerging assessment instruments and 
techniques in areas of structural/chemical and functional neuroimaging and neuropsychol-
ogy, advances in the realms of cell-based therapies and genetics, promising cognitive reha-
bilitation techniques including cognitive remediation and the use of electronic technologies 
including assistive devices and virtual reality, and the emerging ﬁ  eld of complementary and 
alternative medicine.
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Traumatic brain injury future prospects
Traumatic brain injury (TBI) is an extremely common condition, accounting for 50,000 
deaths and 235,000 hospitalizations yearly (Langlois et al 2004). The prevalence of 
individuals with chronic TBI-related problems in the US is 5.3 million (Cohen et al 
2007; Thurman et al 1999) with many manifesting a combination of physical, cognitive 
and behavioral problems. Although this ﬁ  gure is extremely large, it may underestimate 
the true burden of TBI, as many individuals with milder injuries are often unknown to 
the medical system (Krause and Arthur 1999). This is partly because physical impair-
ments, which are easily detectable, are frequently mild or absent after TBI, while the 
more common disabling problems of cognitive and behavioral impairments are often 
overlooked or misdiagnosed by medical professionals. However, it is the latter group 
of problems that prevent participation in expected and desired societal roles and result 
in the greatest burden associated with TBI. In the coming decades, the aging population 
will make this problem even worse, as older individuals are at increased risk of TBI 
and generally have poorer outcomes. This will greatly increase the overall prevalence 
of TBI and add to the societal burden presented by more individuals requiring both 
medical and custodial care.
Although considerable strides have been made in decreasing overall TBI-related 
mortality by the application of evidence-based medicine, many individuals develop 
chronic problems, often resulting in life-long disability. While some pilot projects 
have reported promising ﬁ  ndings, such as decreasing 30-day mortality with pro-
gesterone (Wright et al 2007), most studies examining effectiveness of post-acute 
interventions have failed to deﬁ  nitively demonstrate a therapeutic effect, which is in Neuropsychiatric Disease and Treatment 2008:4(5) 878
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part because of an inadequate understating of both normal 
and pathological cerebral processes.
Future treatment of TBI will require a far more detailed 
understanding of normal cerebral anatomy and physiology 
as well as the pathological and recuperative responses that 
result from trauma than is currently known. Greater clarity 
is required regarding normal brain function as it applies to 
development throughout the lifespan, adaptive responses 
to disease and trauma, as well as to the physiological 
interactions between various cerebral regions that permit 
both simple and complex cognitive processes. Given the 
staggering prevalence of TBI and its impact on activity and 
participation, medical science has expanded its search to 
better assess brain function and the factors that impact injury 
severity and outcome. Not only will new therapies be based 
on this enhanced understanding, but also more speciﬁ  c treat-
ments will likely be better directed to individuals possessing 
unique characteristics. This article will explore emerging 
assessment instruments, advances in the realms of cell-based 
therapies, genetics, promising new rehabilitation techniques, 
and integrative treatments that combine both complementary 
and alternative approaches with typical Western treatments 
that will likely lead to a reduction in TBI-related morbidity 
and improved outcomes.
Neuroimaging
Traditional imaging techniques, such as computerized 
tomography (CT) and conventional magnetic resonance 
imaging (MRI) have proven to be highly effective in identi-
fying macroscopic lesions, which is a necessary component 
in managing acute trauma. However, they have marked 
limitations in assessing microscopic lesions and cerebral 
physiology, such as those associated with diffuse axonal 
injury (DAI) and metabolic alteration. Furthermore, they 
offer little insight into the normal physiology associated 
with behavior and cognition. These issues are being more 
effectively addressed with newer neuroimaging technolo-
gies that are leading science to a more comprehensive under-
standing of the brain, both through imaging its physiology 
during various functional tasks and ﬁ  ner in-vivo micro-
scopic analysis of pathological processes and molecular 
composition in both normal and pathological conditions. 
Although these techniques will provide considerable insight 
into injuries of varying severity, it may be particularly useful 
in identifying individuals with TBI. Typically, individuals 
with mild TBI have normal appearing neuroimaging stud-
ies despite manifesting cognitive and behavioral problems. 
It is possible that enhanced analysis of brain function and 
anatomy following mild TBI may assist in delineating 
the neurophysiologic basis of post-concussion symptoms. 
Given the limitations of conventional imaging technolo-
gies, it is not surprising that they are poorly prognostic 
of outcomes (Diaz-Marchan et al 1996) and offer little 
information regarding the assessment of efﬁ  cacy of TBI-
related treatments. As the mechanisms of cerebral injury 
and repair are better delineated through enhanced imaging, 
new assessment and treatment modalities will be developed 
that can be applied with greater speciﬁ  city than currently 
available to individuals with TBI.
Structural/chemical imaging
Diffusion tensor imaging
Diffuse axonal injury (DAI) is felt to be a major contributor 
to morbidity following TBI, yet because it occurs at a 
micro- rather that macroscopic level, it is poorly imaged 
on standard CT and MRI scans. Diffusion tensor imaging 
(DTI), however, generates images by taking advantage 
of the variability of both the speed and direction of water 
diffusion in-vivo. Water diffuses faster along an axon, a 
phenomenon known as anisotropy, as opposed to across 
it, a phenomenon known as isotropy. White matter tracts 
manifest large fractional anisotropy (FA) values, which can 
be assessed by diffusion tensor technology. This permits 
an in-vivo investigation of ﬁ  ber tract integrity that has 
been correlated with histopathological evidence of DAI 
(MacDonald et al 2007).
DTI has been shown to provide evidence of axonal injury 
in the presence of normal standard MR imaging (Nakayama 
et al 2006), the extent and quantity of white matter injury 
(Xu et al 2007) and the location of maximum white matter 
tract abnormality associated with motor impairment post-
TBI (Yasokawa et al 2007). FA values have been correlated 
with both injury severity and outcomes (Benson et al 2007; 
Huisman et al 2004; Wozniak et al 2007). Along with various 
other imaging modalities, it has the potential to better delin-
eate the normal development of ﬁ  ber tracts that occur in the 
brains of children and adolescents as they acquire increas-
ingly complex cognitive capabilities, such as executive skills, 
that often fail to develop following pediatric TBI. DTI in 
association with other diffusion weighted images, permits a 
greater understanding of the pathophysiological process of 
axonal injury. It does so by examining the individual compo-
nents and time course responsible for decreased anisotrophy, 
such as edema and axonal truncation, potentially identifying 
a therapeutic window for future treatments designed to ame-
liorate DAI (Newcombe et al 2007).Neuropsychiatric Disease and Treatment 2008:4(5) 879
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Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) analyzes the 
concentrations of various metabolites in speciﬁ  c cerebral 
regions, which in pathological states differ from healthy 
tissue. The hardware for MRS is similar to standard MRI, 
requiring only additional software to provide analysis and 
imaging. Data are presented from either a single volume of 
brain, known as single voxel spectroscopy, or as a 2D or 
3D analysis obtained simultaneously over a wider region, 
known as magnetic resonance spectroscopy imaging (MRSI). 
N-acetylaspartic acid (NAA) is present only in neuronal tis-
sue and is one of several key cerebral metabolites measured 
by MRS. Lower than normal levels of NAA are indicative 
of either neuronal loss or abnormal changes in cellular 
function (Demougeot et al 2001), which is associated with 
poorer outcomes post-TBI even in the presence of normal 
appearing standard neuroimages (Garnett et al 2000). Other 
metabolites of interest measured by MRS include creatine 
(energy utilization marker), choline (marker of cell mem-
brane disruption, inﬂ  ammation and changes in myelination), 
myo-inositol (astrocyte marker), glutamate and lactate, which 
along with NAA have been correlated to various outcomes 
when obtained at various times post-TBI (Marino et al 2007; 
Shutter et al 2004; Signoretti et al 2002).
MRS appears to be an effective means to assess for 
injury after mild TBI, revealing whole brain reductions in 
NAA associated with cerebral atrophy despite the absence of 
focal lesions detected on conventional MRI. This provides 
strong evidence that mild TBI can result in widespread 
damage (Cohen et al 2007). Additional MRS data suggest 
that older individuals are susceptible to a greater degree of 
damage occurring from comparable injury severities than 
their younger counterparts, which may partially account for 
poorer outcomes in the elderly (Cohen et al 2007). MRS 
data can provide information on TBI-induced physiological 
changes, cerebral regions susceptible to injury, individual 
susceptibility to injury, and the predictive role of metabolic 
alterations on outcomes post-TBI not feasible with conventional 
imaging. Longitudinal MRS studies can examine the extent 
and location of concentration changes over time in association 
with speciﬁ  c cognitive abilities. This provides information 
regarding the physiological and chemical modiﬁ  cations that 
impact either favorably or unfavorably on recovery occurring 
over time post injury (Yeo et al 2006), although further stud-
ies are warranted to determine the best times to acquire data. 
With greater understanding provided by MRS regarding the 
molecular changes associated with the acute and reparative 
processes of  TBI and at what time post-injury these changes 
occur, comes the possibility of developing treatments to 
ameliorate pathological alterations and improve outcomes.
Functional neuroimaging
Functional magnetic resonance
Functional MRI (fMRI) assesses the combination of regional 
blood ﬂ  ow and local metabolic activity that occurs during 
cerebral activity. It takes advantage of the differing magnetic 
properties of oxygenated and de-oxygenated hemoglobin, 
known as the blood oxygen level difference (BOLD) 
response. The BOLD response is altered during functional 
activity and is represented as a bright signal on fMRI, identi-
fying a region that is relatively more metabolically active than 
surrounding tissue. It offers good temporal and spatial resolu-
tion, both of which are better than those obtained by either 
SPECT or traditional PET scans, and the lack of radiation 
permits multiple imaging. However, several factors impact 
the interpretation of fMRI data, including a subject’s ability 
to fully cooperate, medication effects, adequacy of cerebral 
blood ﬂ  ow, cerebral dominance, and inadvertent subject 
movement during image acquisition. When interpreting data, 
it is important to consider the multitude of possible reasons 
accounting for altered activation patterns, such as establish-
ment of alternative pathways, practice effects, or differences 
in performance difﬁ  culty that exist between injured subjects 
and normal controls. One must also consider lesion location 
and size, time from injury, age, and study design (cross-
sectional versus longitudinal). Also, only simple functional 
tasks can be performed in the scanner, limiting its utility. It 
is currently used as a research tool, although in the future it 
may be used to guide treatment by better delineating regions 
responsible for cognitive processes, examining changes in 
activation over time and in response to speciﬁ  c treatments, 
and assist in determining both optimal dosing and timing of 
treatments.
Functional near infrared spectroscopy
Functional near infrared spectroscopy (fNIRS) is an emerging 
technology that assesses optical properties of tissues in-vivo, 
permitting investigation of cerebral metabolism. Because 
oxygenated and deoxygenated hemoglobin have unique 
optical characteristics, fNIRS can measure functional activity 
in-vivo, just as fMRI does by measuring the magnetic proper-
ties of the same compounds. Researchers have demonstrated 
fNIRS ability to assess cerebral activity in humans associated 
with motor or cognitive tasks (Villringer Chance 1997).
Although research examining its utility to assess function 
after TBI is limited to date, it offers some potential advantages Neuropsychiatric Disease and Treatment 2008:4(5) 880
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over fMRI in that it is a portable system that it is less susceptible 
to motion artifacts, is less expensive and permits examination 
of changes during tasks in a more ecologically valid environ-
ment. Additionally, obtaining fNIRS is not prevented by the 
host of contraindications associated with MRI. Accordingly, 
it offers the possibility of imaging cerebral activity associated 
with activities not feasible within a MR scanner and in environ-
ments more appropriate for the behavior or function. Its por-
tability may also make it a means to assess metabolic changes 
during speciﬁ  c rehabilitation activities, offering good temporal 
resolution that may provide opportunities to better develop 
treatments and assess their physiological underpinnings.
Although it is an emerging technology, some studies have 
shown correlations with fMRI (Obrig et al 2000; Okamoto 
et al 2004), suggesting it is a promising venue to examine 
cerebral activity in more comfortable and varied settings, 
realizing that additional studies are needed to better correlate 
the two technologies. However, current fNIRS technology 
permits imaging only through the top 2–3 mm of cerebral 
cortex and 1 cm lateral to the topical sensors, with other 
difﬁ  culties persisting regarding the use of cranial reference 
points, reduction of the optical signal by non-cerebral tissue, 
the impact of pigmentation on signal detection and limited 
spatial resolution (Irani et al 2007).
Transcranial magnetic stimulation
Non-invasive stimulation produced by magnetic pulses or 
direct current offers the opportunity to study the functional 
neuroanatomy of the brain and is a means to test hypotheses 
pertaining to cognitive neurosciences. Transcranial magnetic 
stimulation (TMS) uses short magnetic pulses that are pro-
vided in three different patterns (single pulse, paired pulse or 
repetitive pulses), resulting in either an increase or decrease 
in cortical excitability. Altering cortical excitability permits 
a non-invasive means to examine the impact of “virtual 
lesions” in otherwise healthy tissue as well as the impact of 
enhanced excitability on various cognitive or motor tasks. 
This will lead to a more detailed understanding of cerebral 
physiology and the neuroanatomical correlates of impaired 
function resulting from disease or trauma. Current applica-
tions of TMS after TBI include measuring the excitability 
of central motor pathways, mapping cortical representations, 
and predicting motor recovery (Caramia et al 1996; Netz 
et al 1997; Turton et al 1996) while possible future uses 
may include it as a therapy for various brain injury related 
cognitive and motor impairments.
Repetitive TMS (rTMS) applies a repeated train of 
magnetic pulses at either low or high frequencies, typically 
producing a suppression or enhancement of cortical 
excitability respectively (Berardelli et al 1998; Chen et al 
1997; Muellbacher et al 2000). The change in excitability 
incurred by rTMS has been shown to last beyond the appli-
cation of the magnetic pulses (Peinemann et al 2004), pos-
sibly as a result of inducing long-term potentiation (Siebner 
Rothwell 2003). This lasting change creates an environ-
ment that may be supportive of neural plasticity that can be 
exploited as a means to enhance treatment following TBI. 
Although studies to date to improve motor and cognitive 
skills have been small and its efﬁ  cacy remains uncertain 
(McElligott et al 2007), several studies suggest it may be a 
valuable adjunct to traditional rehabilitation techniques to 
improve function (Buteﬁ  sch et al 2004; Hummel et al 2005; 
Khedr et al 2005). Its therapeutic potential has been most 
studied as a means to treat major depression, predominantly 
in subjects refractory to pharmacological intervention, by 
targeting the dorsolateral prefrontal cortex (Fregni et al 2006; 
McNamara et al 2001), with results generally indicating its 
effectiveness is equivalent to electro-convulsive therapy 
(Grunhaus et al 2003). Its primary risk is inducing seizures, 
although strict adherence to recommendations detailing limits 
on stimulation parameters, monitoring guidelines and contra-
indications decreases its incidence (Wassermann 2002).
Potential uses of TMS after TBI in the future include 
enhancing our understanding of neuronal circuits by better 
delineating their mechanisms, location, timing, lateralization 
and adaptability to injury and experience (Floel and Cohen 
2007) and exploiting its impact on cerebral plasticity to 
ameliorate brain injury-related morbidity. As opposed to 
fMRI and PET, it is independent of subject performance, 
although subcortical structures cannot be directly stimulated 
by this method.
Magnetoencephalography
Magnetoencephalography (MEG) involves the detection of 
magnetic ﬁ  elds generated by electrical currents in the brain in 
response to neuronal activity, which unlike electrical activity 
measured by EEG, are not distorted by other tissues. This per-
mits precise spatial localization of its generating source with 
temporal resolution measured in fractions of a millisecond. 
MEG therefore permits the tracking of brain activity in real 
time with precise localization. Data derived from MEG may 
be integrated with standard MR images to generate magnetic 
source images (MSI), which provide a visual representation 
of the activated cerebral region. The precise temporal and 
spatial resolution of MEG makes it possible to not only 
examine which regions are activated during speciﬁ  c cognitive Neuropsychiatric Disease and Treatment 2008:4(5) 881
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tasks but also the relative time course of activations, which 
is critical in understanding cognitive processes that involve 
geographically discrete brain regions. Abnormalities in MEG 
signals have been shown to correlate with cognitive difﬁ  cul-
ties in subjects with mild TBI (Lewine et al 2007). By gaining 
a more detailed understanding of where and when neuronal 
circuitry become active and how they change in response to 
injury and rehabilitation, scientists will gain better insights 
into cognitive physiology permitting development of more 
speciﬁ  c treatments and the response to those treatments.
Stem cells
Stem cells (SC) are naturally occurring immature cells that 
are both self-generating and pluripotent, possessing the 
ability under speciﬁ  c conditions to differentiate into various 
cell types. They are derived from 2 broad sources; the inner 
cell mass of 4- to 5-day-old fertilized embryos, known as 
embryonic SC, or adult SC that are obtained from mature 
tissues such as bone marrow, umbilical cord blood, or the 
central nervous system. Because of the considerable ethical 
and political controversy that exists regarding the use of 
embryonic SC, adult SC research has become another venue 
to advance the ﬁ  eld in general. Similar to embryonic SC, adult 
SC have been shown to develop into phenotypically diverse 
cell types under speciﬁ  c conditions. Within the CNS, adult 
neural SC naturally exist in the hippocampus and the subven-
tricular zone, which maintain the ability to generate neurons, 
astrocytes and oligodendrocytes throughout life (Reynolds 
and Weiss 1992) and are presumably responsible for some 
degree of central nervous system homeostasis and repair 
(Garbuzova-Davis et al 2006). However, the persistent abil-
ity to naturally produce neural tissue throughout life cannot 
sufﬁ  ciently repair damage and restore lost function resulting 
from injury and disease, possibly because not enough cells 
are produced, inability of newly produced cells to migrate 
to the region of injury or a microenvironment that is poorly 
conducive for repair (Kim 2007). Enhancing creation of 
neural tissue from SC, either by increasing endogenous 
production or exogenously by transplantation of SC made 
in vitro, represents a novel and promising means to repair 
CNS damage, reverse neurological impairments and restore 
function lost to disease or trauma.
Research to date, predominantly in animals, provides some 
indication of the potential utility of cell-based therapy. Neural 
cells arising from implanted adult SC have been identiﬁ  ed 
in or close to the region of injuries induced in animals, often 
associated with functional improvement (Chen et al 2001; 
Jeong et al 2003; Lee et al 2007; Li et al 2002). This indicates 
that SC not only maintain the ability to differentiate into more 
mature neural cells, but that these progeny migrate to the 
area of injury and may contribute to improved neurological 
function. Functional improvements in humans have also 
been reported, but research here is very limited (Bang et al 
2005; Kondziolka et al 2000; Savitz et al 2004). Although 
intuition suggests the neurological improvements observed 
in these studies arose from replacement of neurons damaged 
by disease or trauma, deﬁ  nitive conclusions remain elusive. 
Other possible explanations for improvement include that SC 
alter the microenvironment by production of growth factors 
(Sanberg et al 2004), provide some degree of neuroprotec-
tion or modulate inﬂ  ammation (Garbuzova-Davis et al 2006). 
More research is needed in order to answer this and other 
questions, which will ultimately help to direct clinical use 
of SC in the future.
Several barriers currently exist preventing more vigorous 
clinical applications of cell based therapies, including the 
ethical concerns associated with embryonic SC, puriﬁ  cation 
of SC cultures, the optimal timing and site of transplanta-
tion, in-vitro production of sufﬁ  cient neural stem cells for 
transplantation that retain the ability to differentiate into 
mature cells, and long-term tracking of transplanted cells 
in humans. Additional obstacles to their therapeutic use 
include optimizing an effective delivery system, overcoming 
rejection of foreign cells and the effects of SC survival after 
delivery. Some advances have recently been made to address 
some these concerns, including genetically engineered human 
neural stem cells that permit cell proliferation and differentia-
tion in-vivo and in-vitro and incorporation of superparamag-
netic iron oxide nanocomposites into SC that permit MRI 
tracking in-vivo without impacting their survival or ability 
to differentiate (Guzman et al 2007; Zhu et al 2006).
Genetics
A great deal of research has been devoted to the prognostica-
tion of TBI, with most studies focusing on easily identiﬁ  able 
factors, such as the Glasgow Coma Scale score, length of 
post-traumatic amnesia, and a host of other injury-related 
characteristics that only partially explain the variance in 
outcomes. This strongly suggests that other factors play a 
signiﬁ  cant role in the severity of and recovery from TBI. 
It is becoming increasingly evident that individual genetic 
factors play an inﬂ  uential role in determining outcomes, with 
several possible genes emerging as candidates.
With the completion of the Human Genome Project, it 
is certain that research examining the genetic role in out-
come prediction will grow tremendously in the near future, Neuropsychiatric Disease and Treatment 2008:4(5) 882
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permitting not only a greater ability to predict recovery, but 
more importantly provide a means for medical science to both 
better understand the pathophysiological processes associ-
ated with TBI and a rationale to develop speciﬁ  c treatments 
that are individualized based on unique genotypes. Several 
variant forms of genes, known as polymorphisms, have been 
identiﬁ  ed as potentially impacting the course of TBI, with 
many more likely to be identiﬁ  ed in the near future. To date, 
genes identiﬁ  ed as either likely or possibly contributing to 
TBI outcomes include apoE4 and apoE promoter genes, 
calcium channel subunit gene, the p53 gene, catechol-o-
methyltranserase gene, D2 receptor gene, and genes coding 
for the production and metabolism of the interleukins, heme-
oxygenase-1 (HO-1), and angiotensin converting enzyme.
It is important to note that many studies examining 
genetic contributions to the course of   TBI are limited by 
the very nature of genetic science. The frequency of speciﬁ  c 
phenotypes is dependent on many factors beyond any one 
individual gene or overall genotype, including but not limited 
to how race and environmental factors impact genetic expres-
sion. Also, although some well-known genetic disorders are 
inherited as a single gene, such as Huntington’s chorea, most 
others are polygenetic, and the inﬂ  uence of any one isolated 
gene is relatively small, which will almost certainly pertain to 
TBI. Furthermore, some distinct genes are physically linked 
such that they are inherited together, despite each having a 
unique function. This is known as linkage disequilibrium 
(LD). This may result in inadvertently identifying the wrong 
gene as impacting TBI if it is in LD with the actual offending 
gene. Also, the modulating role a speciﬁ  c genotype will have 
following TBI will likely depend on the distinct pathology 
present (eg, hemorrhagic versus non-hemorrhagic). For these 
and other reasons, genetic studies need to be sufﬁ  ciently 
powered and be validated once initial ﬁ  ndings are reported 
(Diaz-Arrastia and Baxter 2006), with results interpreted 
cautiously.
APOE
APOE are genes that exist in 3 alleles, ε2, ε3, and ε4. They 
code for variants of apolipoprotein E (apoE) that serve as lipid 
carrier proteins responsible for transporting and distributing 
lipids among cells in the central nervous system (Mahley 
1988). The presence of the ε4 allele has been associated 
with increased risk of several neurological diseases, includ-
ing late onset familial and sporadic Alzheimer’s disease 
(Corder et al 1993; Saunders et al 1993), stroke (McCarron 
et al 1999), amyloid angiopathy, and HIV-related dementia 
(Corder et al 1998). More recently, several investigators have 
associated it with either poorer outcomes after severe TBI 
as measured by the Glasgow Outcome Scale and impaired 
cognitive function (Friedman et al 1999; Jordan et al 1997; 
Sorbi et al 1995; Teasdale et al 1997) or a slower recovery 
after controlling for other covariates (Alexander et al 2007). 
The mechanism by which the ε4 allele impacts outcomes 
is not certain, although it is speculated to adversely effect 
processes involved in cellular membrane maintenance 
and repair (Mahley 1988; Weisgraber et al 1994), calcium 
metabolism (Veinbergs et al 2002), neural plasticity (Mauch 
et al 2001; Nathan et al 1994), and increased amyloid plaque 
deposition (Nicoll et al 1995). Additional evidence suggests 
the presence of the ε4 allele may increase the risk of post-
traumatic seizures (Diaz-Arrastia et al 2003) and late onset 
Alzheimer’s disease after TBI (Mayeux et al 1993; Mortimer 
et al 1985; Mortimer et al 1991), although there have been 
conﬂ  icting results regarding the latter (Fleminger et al 2003; 
Nathoo et al 2003; Teasdale et al 2005). These differences in 
the studies examining the incidence in Alzheimer’s disease 
may be related to methodological issues or the interaction of 
APOE on other factors such as age, gender and race. More 
notably however, the impact of APOE ε4 on outcomes after 
mild TBI is less deﬁ  nitive than in severe TBI, with several 
studies ﬁ  nding no long-term effect associated with its pres-
ence (Chamelian et al 2004; Liberman et al 2002; Ponsford 
et al 2007).
Expression of the APOE gene is inﬂ  uenced by the APOE 
promoter gene, which also exists as one of several polymor-
phisms that can either up or down regulate apoE production. 
Several polymorphisms in the promotor gene are thought 
to increase susceptibility to AD by increasing expression 
of APOE ε4 and the deposition of beta amyloid protein 
(Jordan et al 1997). At least one of these variant promoter 
genes has been associated with poorer outcomes 6 months 
after TBI (Jordan et al 1997), although further conﬁ  rmatory 
studies are needed.
Genes affecting catecholamine function
Catecholaminergic dysfunction is well documented fol-
lowing TBI, manifested by decreased circulating levels 
of dopamine, norepinephrine and epinephrine as well as 
alterations in cortical catecholaminergic receptors (McIntosh 
1994; McIntosh et al 1998; Prasad et al 1992). The beneﬁ  cial 
role of catecholamine administration in animals post-TBI 
has been well known for decades and to a lesser degree in 
humans (McAllister et al 2005). Several genes have been 
identiﬁ  ed that regulate catecholamine metabolism, which 
exist in several polymorphisms that can potentially impact Neuropsychiatric Disease and Treatment 2008:4(5) 883
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cognitive outcomes post TBI. Catechol-o-methyltransferase 
(COMT) codes for an enzyme that inactivates both dopamine 
and norepinephrine. It exists in 3 isoforms, (val/val, val/met 
and met/met), each causing either an increase or decrease 
in enzymatic activity resulting in various levels of either 
neurotransmitter.
The val/val polymorphism coding for COMT results 
in increased enzymatic activity causing decreased levels 
of dopamine and has been associated with impaired cogni-
tive skills post-TBI compared to those without this variant 
(Flashman et al 2004; Jordan et al 1997; McAllister et al 
2005). Research utilizing fMRI revealed differences in acti-
vation patterns during a working memory task depending on 
the presence or absence of the val allele in both control and 
TBI subjects, with additional differences in activation pat-
terns resulting from administration of a dopaminergic agonist 
(McAllister et al 2004). Although this study was small and 
has yet to be replicated, it suggests that variations in COMT 
genotypes modulate not only the location of activation in the 
brain during a speciﬁ  c cognitive task, but also the action of 
administered pharmacological agents. If results of this study 
are replicated, it strongly suggests that the combination of 
genetics, advanced neuroimaging, and pharmacology may 
lead to more targeted treatments for speciﬁ  c individuals.
Catecholiminergic activity is also affected by the dopa-
mine D2 receptor allele, which codes for a dopamine recep-
tor. Various polymorphisms here result in either increased or 
decreased expression of dopamine receptors that may impact 
cognition. A reduction in expression resulting from a speciﬁ  c 
genotype has been associated with impaired cognitive perfor-
mance after TBI, consistent with dopaminergic modulation 
of cognitive function (McAllister et al 2005).
Genes affecting inﬂ  ammation
Interleukin IL-1αand IL-1β are pro-inﬂ  ammatory cytokines 
that are involved in the molecular response to injury, 
contributing to neuronal death (Rothwell 1999). They are 
encoded by genes that are usually in linkage dysequilibrium 
and include IL1A and IL1B. ILRA is a gene that codes for 
a receptor antagonist to IL-1α and IL-1β that modulate 
inﬂ  ammation. All of these genes have various isoforms, 
IL1A*1 and IL1A*2; IL1B*1 and IL1B*2; and ILRA*1 
and ILRA*2. The presence of the IL1A*2 and IL1B*2 
alleles has been associated with increased risk of develop-
ing myasthenia gravis, juvenile rheumatoid arthritis and 
Alzheimer’s disease (Huang et al 1998; Jordan et al 1997; 
McDowell et al 1995; Nicoll et al 2000) in association with 
increased production of IL-1α and IL-1β. All of these genes 
are activated in response to TBI and depending on the speciﬁ  c 
polymorphisms present, appear to modulate neuronal death 
in distinct ways. For example, the ILRA*2 allele has been 
associated with increased incidence of both hemorrhagic 
contusions and subarachnoid hemorrhages post-TBI 
(Hadjigeorgiou et al 2005). Other inﬂ  ammation-regulating 
genes have been identiﬁ  ed, including those coding for inter-
leukin-6 (Winter et al 2004), heme-oxygenase-1, angiotensin 
converting enzyme, which may also impact pathophysiology 
post TBI. The precise mechanism underlying this is unclear as 
inﬂ  ammation plays a dual role following injury, contributing 
to both pathological injury and repair. However, by better 
delineating the processes involved in pathology and repair, 
including examining the role played by genetic polymor-
phisms and its impact on inﬂ  ammation, interventions can 
be better developed in terms of individual speciﬁ  city, timing 
and dosing of treatments.
Growth factors
Interest in central nervous system (CNS) growth factors is 
growing, particularly regarding brain-derived neurotrophic 
factor (BDNF) and peripheral vascular endothelial growth 
factor (VEGF), as they have been associated with neurogen-
esis in the hippocampus, recovery from injury and prevention 
of the effects of Alzheimer’s disease. BDNF is a protein 
that plays a critical role in CNS development (Lewin 1996; 
Lindsay 1996) but is also involved in cerebral plasticity, 
growth, recovery from injury (Binder and Scharfman 2004) 
learning and memory. It also plays a role in the regulation 
of stress and depression by enhancing the effectiveness of 
antidepressant medications (Russo-Neustadt et al 2001) as 
well as processing its own antidepressant properties (Siuciak 
et al 1997). Levels of BDNF have been shown to increase 
in response to exercise (Hicks et al 1998), which has been 
correlated with improved learning. BDNF has been shown 
to impact favorably on axonal growth and neurogenesis 
(Boyd and Gordon 2002; de Groot et al 2006; Goldman 
1998; Pencea et al 2001; Scharfman et al 2005), raising the 
possibility of utilizing it as a means to enhance recovery. 
However, exogenous BDNF results in down regulation of 
speciﬁ  c receptors that appears to block its effectiveness 
(Blaha et al 2000; Xu et al 2004). Therefore, it is likely that 
BDNF needs to be produced endogenously through exercise, 
in order for it to have a favorable impact on recovery.
VEGF has also been shown to be related to neurogenesis 
in the hippocampus, which has been associated with 
improved memory and learning in an animal model (Cao et al 
2004). Similar to BDNF, VEGF levels increase in response to Neuropsychiatric Disease and Treatment 2008:4(5) 884
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exercise and have been shown to improve cognition in rats in 
association with neurogenesis in the hippocampus. (During 
and Cao 2006; Yasuhara et al 2004). These preliminary 
studies suggest a potential role exercise induced production 
of neurotrophic factors may play in recovery of cognitive 
skills following TBI.
Alternative and complementary 
treatments
Alternative and complementary treatments are “therapies 
or diagnostic techniques that are not part of the current 
Western health care system” (McElligott et al 2006, p. 1061). 
They encompass a variety of approaches including herbal 
supplements, homeopathy, hyperbaric oxygen, EEG-based 
therapy, chiropractice, craniosacral therapy, arts and recre-
ational therapies (such as dance, music, art, horticulture), 
and interventions of Asian origin such as mindfulness and 
meditation practice, Tai Chi Chuan, Ayurvedic medicine, 
and acupuncture. Integrative medicine is a medical approach 
that combines alternative and complementary treatments with 
traditional Western techniques and is becoming increasingly 
available throughout the US. Although empirical literature on 
alternative and complementary treatments for humans with 
TBI is sparse with many studies either insufﬁ  ciently powered 
or poorly controlled, their widespread use and popularity 
in the general population and interest among brain injury 
clinicians demands further scientiﬁ  c investigation to better 
determine their future role (Laures and Shisler 2004; Murrey 
2006; Tindle et al 2005; Winnick 2007).
The literature on herbal supplements following TBI is 
limited to commentaries and case studies with very few 
published empirical studies on their effectiveness, raising 
some concerns regarding their safety and interactions with 
other medications, particularly when used without physician 
supervision (Elovic and Zafonte 2001; Spinella and Eaton 
2002). One double-blind, placebo-controlled study exam-
ined the use of homeopathic treatment in subjects with mild 
TBI with results indicating signiﬁ  cant improvement and a 
medium size effect on self-reported functional disability and 
commonly reported TBI symptoms. It is important to note 
however that no research has been published in this area 
since 1999 (Chapman et al 1999).
Several studies have focused on hyperbaric oxygen 
therapy (HBO) in populations with severe TBI (Adamides 
et al 2006; Al-Waili et al 2005; Golden et al 2006; Hardy 
et al 2007; McDonagh et al 2003; Rockswold et al 1992, 
2007; Shi et al 2006). Severe TBI often results in ischemia 
and anaerobic metabolism leading to a destructive chemical 
chain reaction at the cellular and mitochondrial level resulting 
in secondary brain injury or death (Rockswold et al 2007). 
HBO involves exposing the individual to pure oxygen in 
an environment with greater than normal atmospheric pres-
sures. It appears to improve cerebral aerobic metabolism at a 
mitochondrial level (Daugherty et al 2004; Zhou et al 2007), 
although there is some debate as to whether this constitutes 
a promising area for intervention as concerns have been 
raised about oxygen toxicity and the lack of class I evidence 
supporting its efﬁ  cacy (Adamides et al 2006; McDonagh 
et al 2003). Some literature suggests that HBO can decrease 
mortality and improve neuropsychological and functional 
outcomes after severe TBI but there is still insufﬁ  cient evi-
dence to recommend its use (Golden et al 2006; Hardy et al 
2007; McDonagh et al 2003; McElligott et al 2006; Rocks-
wold et al 2007). Current research is focusing on comparing 
the utility of HBO to that of normobaric hyperoxia, a less 
expensive and easier to administer alternative, and examining 
the mechanisms of action of HBO (Rockswold et al 2007).
The successful use of acupuncture for treating TBI-related 
pain, spasticity and altered level of consciousness has been 
reported in several studies (Donnellan 2006; Tamai et al 
2007). In one randomized trial of 30 individuals in post-
traumatic coma, 15 subjects received routine medical care 
combined with acupuncture and point injection therapy while 
15 controls received only standard treatment (He et al 2005). 
Those in the acupuncture condition showed signiﬁ  cantly 
more improvement than controls in language, motor and 
cranial nerve function. The results of another study com-
paring acupuncture to placebo in treating individuals with 
post-TBI facial paralysis using a randomized two group ABA 
design in 50 subjects revealed signiﬁ  cant improvements in the 
acupuncture group as compared to the control group (Zhao 
2003). The utility of another therapy of Asian origin, Tai Chi 
Chuan, has been studied in improving mood, cognition, and 
mobility (Gemmell and Leathem 2006; Shapira et al 2001). 
However, small sample sizes and inadequately controlled 
experimental design limit the conclusions that can be drawn 
from these studies.
Schoenberger et al (2002) examined the effectiveness of 
the Flexyx Neurotherapy System, which combines biofeed-
back and photic stimulation (using glasses with light emitting 
diodes) in an attempt to affect EEG patterns that are known 
to be associated with cognitive dysfunction after TBI. In a 
randomized wait-list control design of 12 subjects, signiﬁ  cant 
improvements in depression, fatigue, memory and learning 
were found. Controlled studies with sufﬁ  cient statistical 
power examining this approach may thus be warranted.Neuropsychiatric Disease and Treatment 2008:4(5) 885
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Mindfulness-based therapy is a Buddhist meditation-based 
technique that utilizes breathing exercises, guided visualiza-
tion and group discussion. Bédard et al (2003) examined the 
impact of a 12-week mindfulness-based approach to reduce 
stress and improve quality of life in individuals with TBI. 
It was modeled on Kabat-Zinn’s mindfulness-based stress 
reduction program and Kolb’s experiential learning cycle 
(Kabat-Zinn 1982; Kolb 1984, p. 724). It endeavored to 
“encourage a new way of thinking about disability and how 
to approach life to bring a sense of acceptance, allowing par-
ticipants to move beyond limiting beliefs”. The researchers 
used a pre-post design with drop-outs as controls and found 
improved quality of life scores on the SF-36. Given the suc-
cess of such interventions in other contexts, further research 
on mindfulness using more rigorous research designs is war-
ranted (Allen et al 2006).
Literature is limited on the impact of music therapy in 
persons with TBI suggesting a possible positive impact 
on mood, socialization, and awareness, with decreases in 
undesired behaviors such as inertia and psychomotor agita-
tion (Baker et al 2005; Formisano et al 2001; Magee and 
Davidson 2002; Magee 2005; Nayak et al 2000; Wheeler et al 
2003). However, the evidence is based on case reports and 
small, largely uncontrolled studies and is thus preliminary in 
nature, indicating the need for further investigation.
In sum, despite some promising early research, there is 
little empirical basis for or against recommending particular 
complementary and alternative treatments. Given the public 
interest in treatments of this kind, the extent to which they 
are already used, and their potential beneﬁ  ts and risks, further 
research is urgently needed. In addition to both short and 
long-term efﬁ  cacy, additional questions regarding subject 
selection, dosing, timing of treatment and concurrent treat-
ments will also need to be addressed.
Cognitive remediation
Cognitive remediation is a widely used approach to restor-
ing function and implementing compensatory strategies 
after brain injury. These interventions fall into three broad 
categories: 1) process-speciﬁ  c remediation, which focuses on 
very targeted areas of cognitive functioning, such as atten-
tion; 2) functional skills training, which focuses on improving 
cognitive functions by improving performance in functional 
activities of daily life; and 3) metacognitive remediation, 
which focuses on self-monitoring and self-regulation through 
the use of “top-down” strategies for addressing a range of 
problems and life situations of varying complexity (Cicerone 
2006). Systematic reviews of cognitive remediation research 
conducted between 1988 and 2002 have identiﬁ  ed over 250 
studies, including 46 well-designed, randomized, controlled 
trials examining remediation of deﬁ  cits after TBI and stroke 
in multiple cognitive domains (Cicerone et al 2000, 2005). 
Cicerone et al (2005, p. 1689) concluded that existing studies 
provide “substantial evidence to support cognitive reha-
bilitation for people with TBI” and have generated practice 
recommendations based on this evidence. Furthermore, they 
recommended that future research focus on treatment and 
patient factors that optimize cognitive rehabilitation outcomes 
rather than merely addressing whether or not cognitive reha-
bilitation is effective (Cicerone et al 2005). This is especially 
relevant given the heterogeneity of individuals with TBI and 
their cognitive deﬁ  cits.
Although some process-speciﬁ  c approaches are well-
supported by research data, there are practical and theoretical 
reasons to incorporate multiple treatments into more holistic, 
multimodal programs of research (Ben-Yishay et al 1985; 
Cicerone et al 2006; Gordon et al 2006; Kaschel et al 2002; 
Ownsworth and Mcfarland 1999; Sohlberg and Mateer 
1987; Sohlberg et al 2000; Wilson 1997; Wilson et al 2005). 
These reasons include the multi-faceted nature of post-TBI 
deﬁ  cits, the inter-dependence of cognitive functions and 
emotions, and the need to facilitate functional change in 
multiple domains. For example, Gordon et al (2006) have 
outlined a theoretically based model for the rehabilitation 
of executive dysfunction that draws on models of cerebral 
function and organization, cognitive behavioral theory, 
and learning theory. The intervention based on this model 
combines top-down and bottom-up approaches, including 
empirically-validated interventions for attention, problem 
solving, and emotional regulation. These are embedded in a 
day-treatment program that also uses “standard” cognitive 
rehabilitation approaches such as memory planners, psycho-
education groups, and social skills training. Despite the fact 
that theoretically-driven multimodal and holistic treatments 
of this kind represent a promising approach to addressing 
the complexity of post-TBI cognitive difﬁ  culties, very few 
randomized controlled trials have been conducted and their 
external validity is poor (Cicerone 2006; Ruff et al 1989; 
Salazar et al 2000). However, there is a growing body of 
evidence that supports the use of such approaches and their 
long-term beneﬁ  ts (Cicerone 2006; Cicerone et al 2004; 
Hashimoto et al 2006; High et al 2006; Malec 2001; Rath 
et al 2003; Sander et al 2001; Sarajuuri et al 2005). Several 
authors have pointed out that future research will need to 
focus on comparing the impact of targeted and multimodal 
holistic interventions and improving the sensitivity and Neuropsychiatric Disease and Treatment 2008:4(5) 886
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speciﬁ  city of outcome measurement in research of this kind 
(Cicerone 2006; Cicerone et al 2006; Gordon et al 2006).
Research on technologically driven cognitive rehabilita-
tion interventions has examined the impact of a variety of 
assistive devices and services to provide cues and memory 
aids for individuals with brain injury and improve cognitive 
functioning through computerized remediation (Bergman 
2003; Gorman et al 2003; Hart et al 2002; Kim et al 2000; 
Tam et al 2003; van den Broek et al 2000; Wilson et al 2005; 
Wright et al 2001a, b). For example, the NeuroPage system is 
an innovative approach that reduces everyday planning and 
memory problems in individuals with brain injury through 
the use of pagers to send pre-arranged cues to remind them 
of tasks that they need to do (eg, take medications or make 
lunch) (Wilson et al 2001, 2003, 2005). In well-designed 
randomized controlled trials, this simple approach was 
shown to signiﬁ  cantly improve memory performance and 
reduce healthcare costs (Wilson et al 2001, 2005). However, 
most of the existing research is not of this caliber, and is 
composed of small, uncontrolled studies, and case reports 
(Bergman 2003; Gorman et al 2003; Kim et al 2000; van den 
Broek et al 2000; Wright et al 2001a, 2001b). Although there 
is evidence to suggest that many clinicians and individuals 
with TBI use or are interested in using newer electronic 
technologies for cognitive rehabilitation, the research litera-
ture has yet to explore the possibilities of these methods in 
any depth (Hart et al 2003; Hart et al 2004; O’Neil-Pirozzi 
et al 2004).
Ecologically valid 
neuropsychological assessment
Neuropsychology has begun to shift from a primary focus 
on diagnostic evaluations designed to identify neuropatho-
logical impairments in speciﬁ  c cognitive domains to greater 
emphasis on the consideration of the functional implications 
of neuropsychological test results and their relationship to 
an individual’s performance of everyday tasks (Rabin et al 
2007; Standen and Brown 2005). More recently, particularly 
in the rehabilitation of individuals with TBI, there has been 
interest in developing measures that assess functional abilities 
to more accurately assess performance in the “real world” 
(Chaytor and Schmitter-Edgecombe 2003; Long and Kibby 
1995; Sbordone 1996; Troster 2000) Tests designed with 
ecological validity in mind, as opposed to traditional neuro-
psychological tests, may be more effective in determining 
the extent to which an intervention improves an individual’s 
performance on everyday cognitive tasks. However, older 
neuropsychological tests that were designed to diagnose 
neuropathology are now used to make predictions about 
real world functioning, yet there is limited research on the 
ecological validity of these tests (Rabin et al 2007; Standen 
and Brown 2005).
More recently, several neuropsychological measures that 
have been designed with ecological validity as a primary 
consideration have made progress towards wider acceptance. 
Most of these measures have been developed in the United 
Kingdom or Canada. They include the Test of Everyday 
Attention (TEA) (Robertson et al  1994), the Behavioral 
Assessment of the Dysexecutive Syndrome (BADS) (Wilson 
et al 1996), the Rivermead Behavioral Memory Test (RBMT) 
(Wilson et al 1985), the Cambridge Test of Prospective 
Memory (CAMPROMPT) (Wilson et al 2004), and the 
Multiple Errands Test (MET) (Alderman et al 2003; Burgess 
et al 2006; Knight et al 2002; Shallice and Burgess 1991). 
They differ from traditional neuropsychological measures 
by focusing on identifying limitations in functional abilities 
rather than discriminating brain injured from healthy people 
or determining the etiology of brain dysfunction (Chaytor 
and Schmitter-Edgecombe 2003). However, there is tremen-
dous variability in the everyday demands facing individuals 
with TBI and they may require very different skill sets. For 
example, the cognitive skills required of a teacher differ 
from those of a ﬁ  reman or a banker. Therefore, most of these 
tests, particularly in the domain of executive functioning, 
lack speciﬁ  city, even when they are sensitive to dysfunction 
(Cicerone et al 2006).
This change in focus of the purpose of neuropsychologi-
cal evaluation is extremely relevant in rehabilitation, where 
the primary goal is treatment planning rather than determin-
ing the type and location of cerebral abnormalities. To ensure 
appropriate treatment, interventions are designed and tailored 
to the individual and the primary role of the neuropsycho-
logical evaluation is to assess the likely implications of the 
ﬁ  ndings on the person’s ability to carry out daily activities 
(Bennett 2001). This then guides the treatment team on the 
type of rehabilitation required and the degree of recovery 
that can reasonably be expected.
Virtual reality
Rapid advances in computer technology have led to the 
creation of multiple virtual reality (VR) applications which 
allow the user to interact with, and become immersed in, 
a computer-generated environment that simulates a real 
world environment (Chute 2002; Rizzo et al 1997). VR tech-
niques can been used as a means to bridge the gap between 
diagnostic measurement tools and ability to function in Neuropsychiatric Disease and Treatment 2008:4(5) 887
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natural environments by using computer-based interactive 
instruments to assess level of functioning in real life simula-
tions, thereby creating more ecologically valid and dynamic 
assessment and training. They also have the capacity to pro-
vide a consistent environment with the potential for inﬁ  nite 
repetitions of the same assessment or training task while 
maintaining the ﬂ  exibility to alter sensory presentations, task 
complexity, response requirements, and the nature and pattern 
of feedback in order to adapt to a user’s unique impairments. 
Thus VR offers the potential to develop both neuropsycho-
logical assessment tools and treatment environments that can 
accurately determine cognitive and functional performance 
by precisely controlling complex stimulus presentation 
(Schultheis et al 2002).
VR is a relatively new approach in rehabilitation 
medicine, yet it offers considerable potential to achieve 
signiﬁ  cant successes in assessment, treatment and improved 
outcome (Johnson et al 1998; Rose et al 2005) The technol-
ogy is rapidly becoming more available and affordable for 
rehabilitation research and the clinical application allows 
ﬂ  exibility for investigators and clinicians to tailor the system 
to particular interests or needs (Baumann et al 2003).
The simulation of real world activities can facilitate the 
evaluation of an individual’s cognitive capacity and perfor-
mance ability for tasks in their own natural environment. 
Additionally, VR tasks can provide a safe setting to assess 
skills that might be too risky in the real world (eg, driving). 
The individual’s own fear of the reaction of others to faulty 
attempts in a natural environment are minimized, and lim-
ited resources that often make trips to a real environment 
difﬁ  cult are easily addressed. In the virtual environment, 
people can go where they like even if they have mobility or 
balance problems. They can make mistakes without suffer-
ing the real, humiliating, or dangerous consequences of their 
errors (Standen and Brown 2005). VR technology can also 
be used for interventions, particularly when sensory, motor 
and cognitive consequences of brain injury combine to make 
environmental interaction difﬁ  cult or dangerous. Interven-
tions have been evaluated in the areas of exercise, yielding 
improvements in reaction times (Grealy et al 1999; Thornton 
et al 2005) and balance (Morganti et al 2007; Sveistrup et al 
2003). In cases where the actual activity is too complex for 
an individual to perform, the VR world can be manipulated to 
break down the activity into multiple and progressively more 
difﬁ  cult tasks, so that the person can learn in a safe realm. VR 
has been used in the area of rehabilitation to increase skills 
for independent living, enhance cognitive performance, and 
improve social skills.
As an assessment tool, VR environments can enhance the 
ecological validity of fMRI research. Typical fMRI experi-
mental designs are often simple, contrived and devoid of real 
life context. While these basic designs are useful in mapping 
primary functional areas of the brain, they provide minimal 
views of the networked brain activity that must occur during 
real life situations when multiple functional areas are called 
upon to guide one’s behavior. Pilot data from an fMRI study 
of memory for spatial navigation showed robust activation 
in multiple cortical regions expected to be involved in the 
task (Baumann et al 2003).
Additionally, assessment of executive functioning skills 
with the Multiple Errands Task has been developed in a VR 
format and was tested on ﬁ  ve patients with executive dys-
function and ﬁ  ve matched controls (McGeorge et al 2001). 
Those with impairments performed more poorly relative to 
controls on the real and virtual versions of the MET. In addi-
tion, there was a signiﬁ  cant correlation between performance 
in the real and virtual task, providing a more discriminating 
method of assessing planning impairments than currently 
available on standardized neuropsychological tests.
VR environments have been used to examine simulated 
driving performance compared to on-road, cognitive, visual-
perceptual, and driving video test results, and have been 
found to be reliable and valid as a screening tool for assessing 
driving performance (Lengenfelder et al 2002; Schultheis 
et al 2007; Wald et al 2000; Wald and Liu 2001). Research 
continues to focus on establishing the reliability and validity 
of different driving simulators (Schultheis et al 2007; Wald 
et al 2000; Wald and Liu 2001). The next step will be to 
progress from evaluation to treatment that improves driving 
skill, much like VR simulators for pilots. VR environments 
have also been created to simulate tasks associated with 
cooking (Christiansen et al 1998; Zhang et al 2001, 2003) 
and shopping (Lee et al 2003). Stability of performance using 
the simulated virtual environment and appears to be a good 
predictor for real world performance.
Overall, virtual technology is less developed as a rehabili-
tative intervention than as a method of assessment (Standen 
and Brown 2005), but recent intervention studies are promis-
ing. Thus effective VR rehabilitation could be adapted for 
individuals to use in inpatient, outpatient and home care as a 
supplement or alternative to conventional therapy.
Conclusions
TBI is a common problem that causes widespread disability. 
Despite the enormity of the problem, few data exist regard-
ing effective treatments beyond the very acute period. Neuropsychiatric Disease and Treatment 2008:4(5) 888
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This is partially because there is insufﬁ  cient understanding 
of both normal and impaired cerebral development and 
function and the factors that impact outcomes post-TBI. 
Advances in the realms of understanding cerebral physi-
ology and function, assessment tools, growth factors and 
genetics in addition to the development of innovative 
research designs will provide the necessary framework 
to better develop treatments that are speciﬁ  c to individu-
als with unique injury characteristics and genotypes. It is 
almost a certainty that any single future intervention will be 
insufﬁ  cient to address the multitude of physical, behavioral 
and cognitive problems caused by TBI. Therefore, as new 
technologies and treatments evolve, it will likely become 
evident that various treatment “cocktails” will emerge that 
combine approaches to assessments and treatment that will 
result in improved recovery by tailoring speciﬁ  c approaches 
to individuals with TBI.
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